Business
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “We made meaningful progress in the first quarter across multiple fronts of our cli
About this update from Indaptus Therapeutics, Inc.
[{"type":"image","alt":"Indaptus Therapeutics","displaySize":"","headline":null,"caption":"Indaptus Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":226,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BUI5bQ5PWkG2QG7XsTNFvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245","width":226,"height":60}},"lazy":false},{"type":"text","content":"NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":340,"tagName":"p"},{"type":"text","content":"Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “We made meaningful progress in the first quarter across multiple fronts of our clinical and research programs. In March, we announced the initiation of the expansion arm of our Phase 1b/2 clinical trial of Decoy20. This arm will evaluate Decoy20 in combination with BeOne’s (formerly known as Beigene) PD-1 checkpoint inhibitor, Tislelizumab, with a focus on safety, dose optimization, and early signals of anti-tumor activity. In addition, we strengthened our intellectual property portfolio with new patents granted in China, Japan, and Israel for our Decoy platform—expanding our intellectual property portfolio. Finally, to date, we have enrolled 32 patients in the weekly dosing among the two Decoy20 dose levels and decided to conclude enrollment for this arm and shift our focus to the combination treatment of Decoy20 with Tislelizumab. Early data from the weekly dosing suggests that Decoy20 is generally well-tolerated, with a favorable safety profile and encouraging signs of clinical benefit, including instances of stable disease. Additionally, we have implemented a cost-reduction plan to focus on the combination study.”","length":1212,"tagName":"p"},{"type":"text","content":"Key recent highlights:","length":22,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":" ",...